Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04438044
Other study ID # ICP-CL-00106
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 18, 2019
Est. completion date December 31, 2023

Study information

Verified date October 2022
Source Beijing InnoCare Pharma Tech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.


Description:

Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with Recurrent/Refractory Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) will be evaluated in approximately 82 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects .


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 61
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Key Inclusion Criteria: 1. Men and women = 18, and =75 years of age 2. Histologically documented PCNSL, or histologically documented systemic diffuse large B-cell lymphoma (DLBCL) for SCNSL. 3. Subjects with refractory or relapsed disease, one prior CNS directed therapy, and = 4 systemic treatments. 4. ECOG performance status of 0-2 5. Able to provide signed written informed consent Key Exclusion Criteria: 1. Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded 2. T-cell lymphoma. 3. Patient requires more than 8 mg of dexamethasone daily or the equivalent. 4. Non-hematological toxicity must recover to = Grade 1 from prior anti-cancer therapy (except for alopecia) 5. Known active infection with HBV, HCV or HIV. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ICP-022
ICP-022 The drug product is a white, round, uncoated tablet

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Beijing Tiantan Hospital affiliated to Capital Medical University Beijing Beijing
China Capital Medical University Xuanwu Hospital Beijing Beijing
China Guangdong General Hospital Guangzhou Guangdong
China Huashan Hospital affiliated to Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Beijing InnoCare Pharma Tech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The efficacy measured by overall response rate (ORR) Cycle 1-6 once every 2 cycles; more than 6 cycles once every 3 cycles. Each cycle is 28 days
Secondary The occurrence of adverse events and serious adverse events The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria every cycle, first cycle every week. Each cycle is 28 days
Secondary The efficacy measured by progression free survival (PFS) cycle 1-6 once every 2 cycles; more than 6 cycles once every 3 cycles. Each cycle is 28 days
Secondary The efficacy measured by duration of response (DOR) cycle 1-6 once every 2 cycles; monre than 6 cycles once every 3 cycles. Each cycle is 28 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04457869 - A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) Phase 2
Recruiting NCT05351593 - Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03964090 - Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) Phase 2
Recruiting NCT05011045 - Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Recruiting NCT05256641 - Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT05398224 - R-MTX-zanbrutinib in Secondary CNS Lymphoma Phase 2
Recruiting NCT05485753 - A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) Phase 1/Phase 2
Recruiting NCT05681195 - Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Phase 2